Simona Dinicola
Research Subjects
Simona Dinicola has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Alessandra Cucina
Department of Surgery “Pietro Valdoni”, Sapienza University of Rome, Via Antonio Scarpa 14, 00161 Rome, Italy
1 shared publication - Ali Cenk Özay
Cyprus International University, Department of Obstetrics and Gynecology, Nicosia, North Cyprus
1 shared publication - Angela Catizone
Department of Anatomy, Histology, Forensic-Medicine and Orthopedics, Section of Histology and Embryology, “Sapienza” University of Rome, 00161 Rome, Italy
1 shared publication B. Fiquet
Affaires scientifiques, Novartis Pharma, Rueil-Malmaison, France
1 shared publication- Gianmarco Fabrizi
Department of Surgery "Pietro Valdoni", Sapienza University of Rome, Rome, Italy
1 shared publication - Giulia Ricci
Dipartimento di Medicina Sperimentale, Università della Campania “Luigi Vanvitelli”, 80138 Napoli, Italy
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by Wiley in Journal of Pregnancy
- Vol. 2025 (1)
Effect of Myo‐Inositol Treatment on Serum Asprosin Levels of Pregnant Women: A Prospective Randomized Controlled Pilot Study
Objectives: Asprosin is a newly discovered adipokine associated with insulin resistance and diabetes mellitus. Currently, its role during gestation is under investigation, as asprosin seems to increase during pregnancy, contributing to the onset of complications, like gestational diabetes. Considering the beneficial effects of myo‐inositol to support the physiological pregnancy, recovering and preventing adverse maternal and fetal outcomes, we aimed to evaluate the effects of its supplementation on serum asprosin levels in pregnant women. Design: We enrolled 40 patients at the early stages of pregnancy and randomly distributed them to a study group, which received 2‐g myo‐inositol and 200‐ μ g folic acid twice a day, or to a control group, which received the sole folic acid. Results: After 20–22 weeks of treatment, we recorded a decrease of serum asprosin values as well as of HOMA‐IR index in the group supplemented with myo‐inositol, while the group that took only folic acid showed an increase in asprosin levels and no worsening of insulin resistance indices (HOMA‐IR index). Limitations: The small number of patients could be a limitation of the study. Conclusions: Asprosin may be modulated by myo‐inositol. This opens the possibility of considering this adipokine as a useful marker of insulin resistance to assess in pregnant women and to efficaciously target in clinical practice. Trial Registration: ClinicalTrials.gov identifier: NCT05943158.
- 1 January 2025
- Published by Wiley in Journal of Pregnancy
- Vol. 2025 (1)
Open AccessEffect of Myo‐Inositol Treatment on Serum Asprosin Levels of Pregnant Women: A Prospective Randomized Controlled Pilot Study
Objectives: Asprosin is a newly discovered adipokine associated with insulin resistance and diabetes mellitus. Currently, its role during gestation is under investigation, as asprosin seems to increase during pregnancy, contributing to the onset of complications, like gestational diabetes. Considering the beneficial effects of myo‐inositol to support the physiological pregnancy, recovering and preventing adverse maternal and fetal outcomes, we aimed to evaluate the effects of its supplementation on serum asprosin levels in pregnant women. Design: We enrolled 40 patients at the early stages of pregnancy and randomly distributed them to a study group, which received 2‐g myo‐inositol and 200‐ μ g folic acid twice a day, or to a control group, which received the sole folic acid. Results: After 20–22 weeks of treatment, we recorded a decrease of serum asprosin values as well as of HOMA‐IR index in the group supplemented with myo‐inositol, while the group that took only folic acid showed an increase in asprosin levels and no worsening of insulin resistance indices (HOMA‐IR index). Limitations: The small number of patients could be a limitation of the study. Conclusions: Asprosin may be modulated by myo‐inositol. This opens the possibility of considering this adipokine as a useful marker of insulin resistance to assess in pregnant women and to efficaciously target in clinical practice. Trial Registration: ClinicalTrials.gov identifier: NCT05943158.
- 16 January 2018
- Published by Wiley in Journal of Pineal Research
- Vol. 64 (4) , e12467
Increase in motility and invasiveness ofMCF7 cancer cells induced by nicotine is abolished by melatonin through inhibition ofERKphosphorylation
Through activation of theERKpathway, nicotine, in both normalMCF‐10A and low‐malignant breast cancer cells (MCF7), promotes increased motility and invasiveness. Melatonin antagonizes both these effects by inhibiting almost completelyERKphosphorylation. As melatonin has no effect on nonstimulated cells, it is likely that melatonin can counteractERKactivation only downstream of nicotine‐induced activation. This finding suggests that melatonin hampersERKphosphorylation presumably by targeting a still unknown intermediate factor that connects nicotine stimulation toERKphosphorylation. Furthermore, downstream ofERKactivation, melatonin significantly reduces fascin and calpain activation while restoring normal vinculin levels. Melatonin also counteracts nicotine effects by reshaping the overall cytoskeleton architecture and abolishing invasive membrane protrusion. In addition, melatonin decreases nicotine‐dependentROCK1/ROCK2 activation, thus further inhibiting cell contractility and motility. Melatonin actions are most likely attributable toERKinhibition, although melatonin could display otherERK‐independent effects, namely through a direct modulation of additional molecular and structural factors, including coronin, cofilin, and cytoskeleton components.
- 16 January 2018
- Published by Wiley in Journal of Pineal Research
- Vol. 64 (4) , e12467
Increase in motility and invasiveness ofMCF7 cancer cells induced by nicotine is abolished by melatonin through inhibition ofERKphosphorylation
Through activation of theERKpathway, nicotine, in both normalMCF‐10A and low‐malignant breast cancer cells (MCF7), promotes increased motility and invasiveness. Melatonin antagonizes both these effects by inhibiting almost completelyERKphosphorylation. As melatonin has no effect on nonstimulated cells, it is likely that melatonin can counteractERKactivation only downstream of nicotine‐induced activation. This finding suggests that melatonin hampersERKphosphorylation presumably by targeting a still unknown intermediate factor that connects nicotine stimulation toERKphosphorylation. Furthermore, downstream ofERKactivation, melatonin significantly reduces fascin and calpain activation while restoring normal vinculin levels. Melatonin also counteracts nicotine effects by reshaping the overall cytoskeleton architecture and abolishing invasive membrane protrusion. In addition, melatonin decreases nicotine‐dependentROCK1/ROCK2 activation, thus further inhibiting cell contractility and motility. Melatonin actions are most likely attributable toERKinhibition, although melatonin could display otherERK‐independent effects, namely through a direct modulation of additional molecular and structural factors, including coronin, cofilin, and cytoskeleton components.